Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcadia Biosciences (RKDA) EBITDA (2016 - 2025)

Arcadia Biosciences filings provide 12 years of EBITDA readings, the most recent being $634000.0 for Q4 2025.

  • On a quarterly basis, EBITDA rose 692.52% to $634000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$489000.0, a 66.85% increase, with the full-year FY2025 number at -$491000.0, up 66.73% from a year prior.
  • EBITDA hit $634000.0 in Q4 2025 for Arcadia Biosciences, up from -$1.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $2.1 million in Q1 2021 to a low of -$9.3 million in Q4 2021.
  • Median EBITDA over the past 5 years was -$1.5 million (2023), compared with a mean of -$1.9 million.
  • Biggest five-year swings in EBITDA: tumbled 324.64% in 2022 and later skyrocketed 692.52% in 2025.
  • Arcadia Biosciences' EBITDA stood at -$9.3 million in 2021, then soared by 54.16% to -$4.2 million in 2022, then soared by 71.89% to -$1.2 million in 2023, then soared by 91.03% to -$107000.0 in 2024, then skyrocketed by 692.52% to $634000.0 in 2025.
  • The last three reported values for EBITDA were $634000.0 (Q4 2025), -$1.2 million (Q3 2025), and -$501000.0 (Q2 2025) per Business Quant data.